登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《LANCET，3月20日，Treatment for severe acute respiratory distress syndrome from COVID-19》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-03-21

  • Treatment for severe acute respiratory distress syndrome from COVID-19

    Michael A Matthay

    J Matthew Aldrich

    Jeffrey E Gotts

    Published:March 20, 2020DOI:https://doi.org/10.1016/S2213-2600(20)30127-2

    In The Lancet Respiratory Medicine, Kollengode Ramanathan and colleagues1 provide excellent recommendations for the use of extracorporeal membrane oxygenation (ECMO) for patients with respiratory failure from acute respiratory distress syndrome (ARDS) secondary to coronavirus disease 2019 (COVID-19). The authors describe pragmatic approaches to the challenges of delivering ECMO to patients with COVID-19, including training health-care personnel, resolving equipment and facilities issues, implementing systems for infection control and personal protection, providing overall support for health-care staff, and mitigating ethical issues.

  • 原文来源：https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30127-2/fulltext
183浏览量
原文链接
相关报告

  • 《LANCET，5月7日，COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-05-09
    • Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study Giulio Cavalli, MD Giacomo De Luca, MD Corrado Campochiaro, MD Emanuel Della-Torre, MD Marco Ripa, MD Diana Canetti, MD et al. Show all authors Published:May 07, 2020DOI:https://doi.org/10.1016/S2665-9913(20)30127-2 Background Mortality of patients with coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARDS), and systemic inflammation is high. In areas of pandemic outbreak, the number of patients can exceed maximum capacity of intensive care units (ICUs), and, thus, these individuals often receive non-invasive ventilation outside of the ICU. Effective treatments for this population are needed urgently. Anakinra is a recombinant interleukin-1 receptor antagonist that might be beneficial in this patient population.
    82浏览量
    原文链接

  • 《LANCET，4月3日，Baricitinib for COVID-19: a suitable treatment? – Authors' reply》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-04-04
    • Baricitinib for COVID-19: a suitable treatment? – Authors' reply Peter J Richardson，Mario Corbellino，Justin Stebbing Published:April 03, 2020DOI:https://doi.org/10.1016/S1473-3099(20)30270-X We thank Ennio Favalli and colleagues for their Correspondence regarding our suggestion to use baricitinib for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections.1, 2 We also appreciate their recognition that inhibition of numb-associated kinase enzymes could indeed be beneficial in preventing virus infectivity via inhibition of clathrin-mediated endocytosis. We welcome the opportunity to more fully explain the possible use of baricitinib in the current pandemic. Indeed, we accept that using a JAK1 and JAK2 inhibitor to treat a viral disease might appear illogical given that the antiviral effects of interferons are largely mediated by the JAK–STAT signalling pathway. However, the administration of pegylated-interferon has not had the beneficial antiviral effects originally hoped for,4 and clinical trials with interferons have yielded inconsistent results, with pathogenic effects of interferons being observed in some viral infections.
    155浏览量
    原文链接